Clinical trials: Schizophrenia Relapse
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia
The purpose of this study is to establish and validate a scale/model that can be used to evaluate the duration of time and factors between short term hospital treatment and subsequent relapse periods in patients with…
- Trial name
- PRE-COG (NCT00358852)
- Testing
- No intervention
- Volunteers
- 2,339 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Schizoaffective Disorder
A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
The purpose of the study is to compare the time to relapse in patients with schizophrenia and schizoaffective disorders receiving risperidone or haloperidol (antipsychotic medications) for at least 1 year.
- Trial name
- NCT00253110
- Testing
- risperidone, haloperidol
- Volunteers
- 396 people
- Sponsor
- Janssen, LP
Schizophrenia, Schizoaffective Disorder
A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess the time for patients to relapse when switched from an oral antipsychotic to one of two doses of long-acting risperidone injection (shots).
- Trial name
- NCT00297388
- Testing
- Risperidone, long-acting injectable
- Volunteers
- 40 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizophrenia Relapse
Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
This prospective longitudinal cohort study will follow patients with schizophrenia who are treated with second generation long-acting injectable antipsychotic medications (LAIs) for 48 weeks to determine the risk of psychotic…
- Trial name
- NCT05473741
- Testing
- Second Generation Long-Acting Injectable Antipsychotic Medications
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
A 20-Year Follow-up of First Episode Psychosis: Longitudinal Effects of Early Treatment Strategies and Relapse
The study aims to address the following questions: 1. Do subgroups defined by early medication choices, relapse, and medication taken over 20 years differ in clinical, cognitive, and functional outcomes? 2.
- Trial name
- NCT07616999
- Where
- China
- Volunteers
- 178 people
- Sponsor
- The University of Hong Kong
Psychosis
Belief-updating, Speech and Psychosis
Psychotic illnesses are characterised by hallucinations, delusions, and disturbed thoughts; symptoms associated with high personal and societal costs.
- Trial name
- BASIS (NCT06042712)
- Volunteers
- 240 people
- Sponsor
- King's College London
Schizophrenia, Schizoaffective Disorder, Depressive Type
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
- Trial name
- APPRAISE (NCT04203056)
- Testing
- Aripiprazole Lauroxil, ARI-ORAL, AL-NCD
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Los Angeles
Schizophrenia, Schizophrenia Relapse
3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
This open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the three years after antipsychotic discontinuation in a sample of functionally recovered first-episode patients with…
- Conditions
- Schizophrenia, Schizophrenia Relapse, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- ADARFEP (NCT02220504)
- Testing
- Antipsychotic treatment discontinuation, Maintenance antipsychotic treatment
- Where
- Spain
- Volunteers
- 68 people
- Sponsor
- Fundación Marques de Valdecilla
Patients With Schizophrenia
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia
Schizophrenia is a severe chronic mental disorder with a long-term treatment. Most antipsychotic (AP) drugs are effective for only 30% to 60% of patients and for many drugs, treatment selection remains a "trial-and-error"…
- Trial name
- PROMISE (NCT05839613)
- Testing
- Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)
- Volunteers
- 400 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Schizophrenia
Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)
The purpose of this study is to examine treatment practices of adult schizophrenia patients by their own doctors, and to assess patient outcomes when treated with long-acting risperidone injection over a two-year period of…
- Trial name
- SOURCE (NCT00246194)
- Testing
- risperidone (RISPERDAL CONSTA)
- Where
- United States
- Volunteers
- 532 people
- Sponsor
- Janssen, LP
Schizophrenia, Schizophrenia and Disorders With Psychotic Features
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
The main objective of the trial is to evaluate, how long an antipsychotic relapse-prevention should be continued and to which time a patient with schizophrenia is protected enough, so that a withdrawal or reduction of the…
- Conditions
- Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders
- Trial name
- NCT02307396
- Testing
- Olanzapine, Amisulpride, Risperidone
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Technical University of Munich
Schizophrenia
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment.
- Trial name
- NCT03351244
- Testing
- BI 409306
- Where
- 59 sites in United States, Canada and 5 more
- Volunteers
- 264 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of…
- Trial name
- NCT04959032
- Testing
- Lumateperone 42 mg
- Where
- 43 sites in United States, Bulgaria and 2 more
- Volunteers
- 592 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
The goal of this project is to show that the best possible option for preventing relapses in patients suffering from first episode (<1 year of anti-psychotic medication) or early phase (< 5 years of lifetime exposure to…
- Trial name
- PRELAPSE (NCT02360319)
- Testing
- Any FDA approved antipsychotic agent, aripiprazole long acting injectable formulation
- Where
- 39 sites in United States
- Volunteers
- 489 people
- Sponsor
- Vanguard Research Group
Schizophrenia, Schizoaffective Disorder
Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors
This study is dedicated to achieving a better understanding of how to identify patterns that indicate someone might be at high risk for relapse in schizophrenia or schizoaffective disorder.
- Trial name
- NCT02224430
- Testing
- schizophrenia/schizoaffective disorder.
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Schizophrenia, Schizoaffective Disorder
AIMHI NT Relapse Prevention Trial
A new treatment for indigenous people with mental illness in remote communities has been developed. The study hypothesis is that this new treatment will result in better outcomes for clients and carers than the outcomes of…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychoses, Substance Induced, Depression
- Trial name
- NCT00192582
- Testing
- Motivational Interview with care plan and education
- Where
- Australia
- Volunteers
- 90 people
- Sponsor
- Menzies School of Health Research
Schizophrenia
To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia is a brain disease. The condition may be associated with acute psychotic episodes and long-term disability despite remission from the acute symptoms.
- Trial name
- NCT00150176
- Testing
- Asenapine - Open Label, Asenapine - Double Blind
- Volunteers
- 831 people
- Sponsor
- Organon and Co
Schizophrenia Spectrum Disorders
Health Outcomes Via Positive Engagement in Schizophrenia
This is an observational study where digital, clinical and health utilization data are collected from individuals with schizophrenia spectrum disorders who have been recently discharged from a psychiatric hospitalization.
- Trial name
- HOPE-S (NCT04230590)
- Testing
- Observational
- Where
- Singapore
- Volunteers
- 100 people
- Sponsor
- Institute of Mental Health, Singapore
Relapse Management
Relapse Management Group Psychoeducation Program
This study was planned to be conducted between February and March 2026, with a total of 60 patients diagnosed with schizophrenia who met the inclusion criteria and were followed at the community mental health center in the…
- Trial name
- NCT07327944
- Testing
- Relapse Management Group Psychoeducation Program
- Volunteers
- 60 people
- Sponsor
- Ankara Etlik City Hospital